Type 2 Diabetes Trial, Recruiting NCT06837103 Sponsor: LMC Diabetes & Endocrinology Ltd. Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Type 2 Diabetes Trial, Recruiting

NCT06837103
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 years or older
  • People who have been clinically diagnosed with type 2 diabetes for at least one year
  • People who are currently using at least one medication to help manage blood sugar
  • People who are either a Sun Life group benefits member who starts using a specific glucose monitoring device through Lumino Health™ Pharmacy and completes an initial pharmacist consultation, or who completes two or more diabetes coaching consultations, or who have private health insurance and use a fingerstick blood glucose monitor
  • People whose HbA1c (a measure of average blood sugar over roughly three months) is 7.0% or higher at the start of the study
  • People who have had at least one HbA1c reading recorded in the six months before joining the study
  • People who have been using a specific type of glucose monitoring device (called an intermittently scanned continuous glucose monitor) exclusively for at least three months
  • People who are willing and able to provide informed consent to participate

Who may not be able to join:

  • People who have a history of using insulin
  • People who are pregnant or breastfeeding at the time of enrolment, or who become pregnant during the study
  • People whose kidneys are not functioning well enough (specifically, an eGFR below 30 ml/min/1.73m²) (confirm with trial site)
  • People who have previously used a continuous glucose monitoring device for more than three months
  • People whose diabetes medications or doses have changed, or are expected to change, within 30 days of their study start date

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
LMC Diabetes & Endocrinology Ltd.
Registry
ClinicalTrials.gov
Start date
9 April 2025
Est. completion
1 May 2026

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Change in HbA1c

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov